Stem cell transplantation in patients with systemic AL amyloidosis referred for transplant after suboptimal responses to bortezomib-based initial therapy

Bone Marrow Transplant. 2017 Jun;52(6):936-937. doi: 10.1038/bmt.2017.47. Epub 2017 Apr 10.

Authors

S W Wong¹, D Larivee², M Warner³, K A Sprague^{2

3}, T Fogaren^{2

3}, R L Comenzo^{2

3}

Affiliations

¹ Department of Medicine, University of California San Francisco School of Medicine, San Francisco, CA, USA.
² Department of Medicine, Division of Hematology-Oncology, Tufts Medical Center, Boston, MA, USA.
³ Division of Hematology-Oncology, The John C Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA, USA.

PMID: 28394371
DOI: 10.1038/bmt.2017.47

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Autografts
Bortezomib / administration & dosage*
Female
Humans
Immunoglobulin Light-chain Amyloidosis / blood
Immunoglobulin Light-chain Amyloidosis / therapy*
Induction Chemotherapy*
Male
Middle Aged
Stem Cell Transplantation*

Substances

Bortezomib